化合物ST-1535 T28861

Product Introduction
Bioactivity


英文名: ST-1535

描述: ST 1535 是有效的，具有口服活性的 A2A 腺苷受体拮抗剂。ST 1535 显示出抗帕金森病活性和抗震颤作用。

体外活性: ST-1535 在经人类A2A腺苷受体克隆的细胞中，竞争性拮抗A2A腺苷激动剂NECA对cAMP的影响（IC50=353±30 nM），并在经人类A1腺苷受体克隆的细胞中竞争性拮抗A1腺苷激动剂CHA对cAMP的影响（IC50=510±38 nM）。[1]

体内活性: ST 1535, at oral doses of 5 and 10 mg/kg, antagonizes catalepsy induced by intracerebroventricular administration of the A2A adenosine agonist CGS 21680 (10 microg/5 microl) in mice. At oral doses ranging between 5 and 20 mg/kg, ST 1535 induces hypermotility and antagonizes haloperidol-induced catalepsy in mice up to 7 h. Oral ST 1535, at 1.25 and 2.5 mg/kg, potentiates L-dopa effects in reducing haloperidol-induced catalepsy. [1]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 9 mg/mL (33.05 mM)


关键字: ST1535 | ST-1535 | ST 1535

相关产品: Namodenoson | Xanthine amine congener | APNEA | PF-02575799 | CHEMBL241987 | Selodenoson | Acefylline | LAS101057 | PSB 0777 ammonium hydrate | MRS-1706

相关库: Anti-Neurodegenerative Disease Compound Library | Neurotransmitter Receptor Compound Library | ReFRAME Related Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Neuronal Signaling Compound Library | GPCR Compound Library | Inhibitor Library | Bioactive Compound Library

化合物ST-1535 T28861信息由TargetMol中国为您提供，如您想了解更多关于化合物ST-1535 T28861报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途